Omalizumab or Xolair can lower risk of food allergies in kids, adults: NIH
HQ Team February 26, 2024: An asthma drug, omalizumab, can “significantly” reduce the risk of allergic reactions caused by multiple foods among children.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
HQ Team February 26, 2024: An asthma drug, omalizumab, can “significantly” reduce the risk of allergic reactions caused by multiple foods among children.
HQ Team February 19, 2024: The Food and Drug Administration (FDA) has approved Genetech’s Xolair (omalizumab) injection for severe food allergies in certain adults.